Preservation of Pancreatic β-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women
- Thomas A. Buchanan123,
- Anny H. Xiang34,
- Ruth K. Peters34,
- Siri L. Kjos23,
- Aura Marroquin1,
- Jose Goico1,
- Cesar Ochoa1,
- Sylvia Tan4,
- Kathleen Berkowitz2,
- Howard N. Hodis134 and
- Stanley P. Azen34
- 1Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California
- 2Department of Obstetrics and Gynecology, University of Southern California Keck School of Medicine, Los Angeles, California
- 3Diabetes Research Center, University of Southern California Keck School of Medicine, Los Angeles, California
- 4Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California
Type 2 diabetes frequently results from progressive failure of pancreatic β-cell function in the presence of chronic insulin resistance. We tested whether chronic amelioration of insulin resistance would preserve pancreatic β-cell function and delay or prevent the onset of type 2 diabetes in high-risk Hispanic women. Women with previous gestational diabetes were randomized to placebo (n = 133) or the insulin-sensitizing drug troglitazone (400 mg/day; n = 133) administered in double-blind fashion. Fasting plasma glucose was measured every 3 months, and oral glucose tolerance tests (OGTTs) were performed annually to detect diabetes. Intravenous glucose tolerance tests (IVGTTs) were performed at baseline and 3 months later to identify early metabolic changes associated with any protection from diabetes. Women who did not develop diabetes during the trial returned for OGTTs and IVGTTs 8 months after study medications were stopped. During a median follow-up of 30 months on blinded medication, average annual diabetes incidence rates in the 236 women who returned for at least one follow-up visit were 12.1 and 5.4% in women assigned to placebo and troglitazone, respectively (P < 0.01). Protection from diabetes in the troglitazone group 1) was closely related to the degree of reduction in endogenous insulin requirements 3 months after randomization, 2) persisted 8 months after study medications were stopped, and 3) was associated with preservation of β-cell compensation for insulin resistance. Treatment with troglitazone delayed or prevented the onset of type 2 diabetes in high-risk Hispanic women. The protective effect was associated with the preservation of pancreatic β-cell function and appeared to be mediated by a reduction in the secretory demands placed on β-cells by chronic insulin resistance.
Address correspondence and reprint requests to Thomas A. Buchanan, Room 6602 GNH, 1200 N. State St., Los Angeles, CA, 90033. E-mail:.
Received for publication 18 March 2002 and accepted in revised form 5 June 2002.
K.B. is currently affiliated with the School of Medicine, University of California at Irvine, Irvine, California.
AIRg, acute insulin response to intravenous glucose; DI, disposition index; GDM, gestational diabetes mellitus; HR, hazard ratio; IVGTT, intravenous glucose tolerance test; Kg, glucose disappearance rate; OGTT, oral glucose tolerance test; SI, insulin sensitivity; TRIPOD, Troglitazone in Prevention of Diabetes.